Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak Jie Jin; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Johannes Drach; Markus Raderer; Jiri Mayer; Juliana Pereira; Gayane TumyanLancet oncology v. 19, n. 11, p. 1449-1458, 2018New York 2018Online access. The library also has physical copies. |
2 |
Material Type: Article
|
![]() |
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 studyGregor Verhoef Tadeusz Robak; Huiqiang Huang; Halyna Pylypenko; Noppadol Siritanaratkul; Juliana Pereira; Johannes Drach; Jiri Mayer; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Andrew Cakana; Helgi van de Velde; Franco CavalliHaematologica Pavia v. 102, n. 5, p. 895-902, 2017Pavia 2017Online access. The library also has physical copies. |
3 |
Material Type: Article
|
![]() |
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)Tadeusz Robak Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Juliana PereiraLeukemia & lymphoma v. 60, n. 1, p. 172-179, 2019Abingdon 2019Online access. The library also has physical copies. |
4 |
Material Type: Conference Paper
|
![]() |
Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 studyTadeusz Robak Huiqiang Huang; Jie Jim; Jun Shu; Ting Liu; Olga S Samailova; Juliana Pereira; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii A Osmanov; Julia Alexeeva; Jiri Mayer; Xiaonan Hong; Yoshiharu Maeda; Brendan Rooney; Helgi van de Velde; Franco Cavalli; Annual Meeting and Exposition / ASH 2014 (56. San Francisco/EUABlood New York v. 124, n. 21, res. 4412, suppl, 2014New York 2014Online access. The library also has physical copies. |
5 |
Material Type: Article
|
![]() |
Bortezomib-based therapy for newly diagnosed mantle-cell lymphomaTadeusz Robak Huiqiang Huang; Jie Jun; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylpenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco CavalliThe New England Journal of Medicine Boston v. 372, n. 8, p. 944-953, 2015Boston 2015Available at FM - Fac. Medicina (BCSEP 093 2015 )(GetIt) |
6 |
Material Type: Article
|
![]() |
Synthesis and Applications of tert-ButanesulfinamideRobak, MaryAnn T ; Herbage, Melissa A ; Ellman, Jonathan AChemical reviews, 2010-06, Vol.110 (6), p.3600-3740 [Peer Reviewed Journal]United States: American Chemical SocietyFull text available |
7 |
Material Type: Article
|
![]() |
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upEichhorst, B. ; Robak, T. ; Montserrat, E. ; Ghia, P. ; Hillmen, P. ; Hallek, M. ; Buske, C.Annals of oncology, 2015-09, Vol.26, p.v78-v84 [Peer Reviewed Journal]England: Elsevier LtdFull text available |
8 |
Material Type: Article
|
![]() |
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upEichhorst, B. ; Robak, T. ; Montserrat, E. ; Ghia, P. ; Niemann, C.U. ; Kater, A.P. ; Gregor, M. ; Cymbalista, F. ; Buske, C. ; Hillmen, P. ; Hallek, M. ; Mey, U.Annals of oncology, 2021-01, Vol.32 (1), p.23-33 [Peer Reviewed Journal]England: Elsevier LtdFull text available |
9 |
Material Type: Article
|
![]() |
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaSeymour, John F ; Kipps, Thomas J ; Eichhorst, Barbara ; Hillmen, Peter ; D’Rozario, James ; Assouline, Sarit ; Owen, Carolyn ; Gerecitano, John ; Robak, Tadeusz ; De la Serna, Javier ; Jaeger, Ulrich ; Cartron, Guillaume ; Montillo, Marco ; Humerickhouse, Rod ; Punnoose, Elizabeth A ; Li, Yan ; Boyer, Michelle ; Humphrey, Kathryn ; Mobasher, Mehrdad ; Kater, Arnon PThe New England journal of medicine, 2018-03, Vol.378 (12), p.1107-1120 [Peer Reviewed Journal]United States: Massachusetts Medical SocietyFull text available |
10 |
Material Type: Article
|
![]() |
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaBrown, Jennifer R. ; Eichhorst, Barbara ; Hillmen, Peter ; Jurczak, Wojciech ; Kaźmierczak, Maciej ; Lamanna, Nicole ; O’Brien, Susan M. ; Tam, Constantine S. ; Qiu, Lugui ; Zhou, Keshu ; Simkovic, Martin ; Mayer, Jiri ; Gillespie-Twardy, Amanda ; Ferrajoli, Alessandra ; Ganly, Peter S. ; Weinkove, Robert ; Grosicki, Sebastian ; Mital, Andrzej ; Robak, Tadeusz ; Osterborg, Anders ; Yimer, Habte A. ; Salmi, Tommi ; Wang, Megan-Der-Yu ; Fu, Lina ; Li, Jessica ; Wu, Kenneth ; Cohen, Aileen ; Shadman, MazyarThe New England journal of medicine, 2023-01, Vol.388 (4), p.319-332 [Peer Reviewed Journal]United States: Massachusetts Medical SocietyFull text available |